Cited by 476Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsCancer-related cognitive impairment studies

The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.

Pittsburgh Compound B Imaging and Prediction of Progression From Cognitive Normality to Symptomatic Alzheimer Disease

Open access

Morris, John C., Roe, Catherine M., Grant, Elizabeth A., Head, Denise, Storandt, Martha, Goate, Alison M., Fagan, Anne M., Holtzman, David M., Mintun, Mark A.·2009·Archives of Neurology

DOI 10.1001/archneurol.2009.269PMC PMC2798814

Open this paper in CoChat — free account Open PDF

Abstract

OBJECTIVE: To determine whether preclinical Alzheimer disease (AD), as detected by the amyloid-imaging agent Pittsburgh Compound B (PiB) in cognitively normal older adults, is associated with risk of symptomatic AD. DESIGN: A longitudinal cohort study of cognitively normal older adults assessed with positron emission tomography (PET) to determine the mean cortical binding potential for PiB and followed up with annual clinical and cognitive assessments for progression to very mild dementia of the Alzheimer type (DAT). SETTING: The Alzheimer's Disease Research Center, Washington University, St Louis, Missouri. PARTICIPANTS: One hundred fifty-nine participants with a mean age of 71.5 years with a Clinical Dementia Rating (CDR) of 0 on a PET PiB scan at baseline. MAIN OUTCOME MEASURE: Progression from CDR 0 to CDR 0.5 status (very mild dementia). RESULTS: Twenty-three participants progressed to CDR 0.5 at follow-up assessment (range, 1-5 assessments after PET PiB). Of these, 9 also were diagnosed with DAT. Higher mean cortical binding potential values for PiB (hazard ratio, 4.85; 95% confidence interval, 1.22-19.01; P = .02) and age (hazard ratio, 1.14; 95% confidence interval, 1.02-1.28; P = .03) predicted progression to CDR 0.5 DAT. The CDR 0.5 DAT group showed decline in 3 cognitive domains (episodic memory, semantic memory, and visuospatial performance) and had volume loss in the parahippocampal gyrus (includes entorhinal cortex) compared with individuals who remained at CDR 0. CONCLUSION: Preclinical AD as detected by PET PiB is not benign, as it is associated with progression to symptomatic AD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1001/archneurol.2009.269

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

“Mini-mental state”
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest
Desikan, R. S., Ségonne, F., Fischl, B., Quinn, B. T., Dickerson, B. C., Blacker, D., Buckner, R. L., Dale, A. M., Maguire, R. P., Hyman, B. T., et al. (2006) · NeuroImage · doi:10.1016/j.neuroimage.2006.01.021 · Cited by 13,324
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Self-citation
Co-planar stereotaxic atlas of the human brain : 3-dimensional proportional system : an approach to cerebral imaging
Talairach, J., Tournoux, P., & Rayport, M. (1988) · Thieme eBooks · Cited by 5,058
Manual for the Wechsler Adult Intelligence Scale.
Wechsler, D. (1955) · Psychological Corp. eBooks · Cited by 4,941
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Mild Cognitive Impairment Represents Early-Stage Alzheimer Disease
Morris, J. C., Storandt, M., Miller, J. P., McKeel, D. W., Price, J. L., Rubin, E. H., & Berg, L. (2001) · Archives of Neurology · doi:10.1001/archneur.58.3.397 · Cited by 1,871
Self-citation
Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study
Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700
Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data
Logan, J., Fowler, J. S., Volkow, N. D., Wang, G., Ding, Y., & Alexoff, D. L. (1996) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199609000-00008 · Cited by 1,515

Show all 57 references

Sorted by citations

Items 301–400 of 469

Empirically Defining Trajectories of Late-Life Cognitive and Functional Decline
Hochstetler, H. M., Initiative, A. D. N., Trzepacz, P. T., Wang, S., Yu, P., Case, M. G., Henley, D. B., Degenhardt, E. K., Leoutsakos, J., & Lyketsos, C. G. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150563 · Cited by 17
Biomarker evidence for uncoupling of amyloid build‐up and toxicity in Alzheimer's disease
Zetterberg, H., & Blennow, K. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.07.002 · Cited by 16
Local and distributed PiB accumulation associated with development of preclinical Alzheimer's disease
Brier, M. R., McCarthy, J. E., Benzinger, T. L. S., Stern, A., Su, Y., Friedrichsen, K. A., Morris, J. C., Ances, B. M., & Vlassenko, A. G. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.10.025 · Cited by 16
Self-citation
Palmomental Reflex a Relevant Sign in Early Alzheimer’s Disease Diagnosis?
Gabelle, A., Gutierrez, L., Dartigues, J., Ritchie, K. A., Touchon, J., & Berr, C. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150436 · Cited by 16
Examining the Complicated Relationship Between Depressive Symptoms and Cognitive Impairment in Preclinical Alzheimer Disease
Javaherian, K., Newman, B. M., Weng, H., Hassenstab, J. J., Xiong, C., Coble, D. W., Fagan, A. M., Benzinger, T. L. S., & Morris, J. C. (2018) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000284 · Cited by 16
Self-citation
Neuropsychiatric Symptoms and Alzheimer Disease Biomarkers Independently Predict Progression to Incident Cognitive Impairment
Babulal, G. M., Chen, L., Murphy, S. A., Doherty, J. M., Johnson, A. M., & Morris, J. C. (2023) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2023.07.012 · Cited by 15
Self-citation
Analysis of longitudinal diffusion-weighted images in healthy and pathological aging: An ADNI study
Kruggel, F., Masaki, F., & Solodkin, A. (2017) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2016.12.020 · Cited by 16
Adverse driving behaviors are associated with sleep apnea severity and age in cognitively normal older adults at risk for Alzheimer’s disease
Doherty, J. M., Roe, C. M., Murphy, S. A., Johnson, A. M., Fleischer, E., Toedebusch, C. D., Redrick, T., Freund, D., Morris, J. C., Schindler, S. E., et al. (2022) · SLEEP · doi:10.1093/sleep/zsac070 · Cited by 16
Self-citation
Biomarkers for the clinical evaluation of the cognitively impaired elderly: amyloid is not enough
McEvoy, L. K., & Brewer, J. B. (2012) · Imaging in Medicine · doi:10.2217/iim.12.27 · Cited by 15
PET Imaging in Movement Disorders
Maiti, B., & Perlmutter, J. S. (2018) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2018.07.006 · Cited by 15
Adverse driving behaviors increase over time as a function of preclinical Alzheimer's disease biomarkers
Doherty, J. M., Murphy, S. A., Bayat, S., Wisch, J. K., Johnson, A. M., Walker, A. I. B., Schindler, S. E., Ances, B. M., Morris, J. C., & Babulal, G. M. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12852 · Cited by 14
Self-citation
Biomarcadores en la enfermedad de Alzheimer
Ribas, G. G., López-Sendón, J. L., & Caldentey, J. G. (2014) · Revista de Neurología · doi:10.33588/rn.5807.2013394 · Cited by 14
Association of mid-life serum lipid levels with late-life brain volumes: The atherosclerosis risk in communities neurocognitive study (ARIC NCS)
Moazzami, K., Power, M. C., Gottesman, R. F., Mosley, T. H., Lutsey, P. L., Jack, C. R., Hoogeveen, R. C., West, N. A., Knopman, D. S., & Alonso, Á. (2020) · NeuroImage · doi:10.1016/j.neuroimage.2020.117324 · Cited by 14
Quantitative Gradient Echo MRI Identifies Dark Matter as a New Imaging Biomarker of Neurodegeneration that Precedes Tissue Atrophy in Early Alzheimer’s Disease
Kothapalli, S. V. V. N., Benzinger, T. L. S., Aschenbrenner, A. J., Perrin, R. J., Hildebolt, C. F., Goyal, M. S., Fagan, A. M., Raichle, M. E., Morris, J. C., & Yablonskiy, D. A. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210503 · Cited by 15
Self-citation
Pro: Can biomarkers be gold standards in Alzheimer's disease?
Sperling, R. A., & Johnson, K. A. (2010) · Alzheimer s Research & Therapy · doi:10.1186/alzrt41 · Cited by 14
ACR–ASNR Practice Parameter for Brain PET/CT Imaging Dementia
Frey, K. A., Lodge, M. A., MELTZER, C. C., Peller, P. J., Wong, T. Z., Hess, C. P., Petrella, J. R., Sair, H. I., & Subramaniam, R. M. (2015) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000001037 · Cited by 14
Quantitative multimodal imaging in traumatic brain injuries producing impaired cognition
Shah, S. A., Lowder, R. J., & Kuceyeski, A. F. (2020) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000872 · Cited by 12
Recent advances in pre-clinical diagnosis of Alzheimer’s disease
Zhou, J., Benoit, M., & Sharoar, M. G. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00733-4 · Cited by 14
Supporting self-management in early dementia: a contribution towards ‘living well’?
Cheffey, J., Hill, L., Roberts, G. A., & Marlow, R. (2013) · Advances in Psychiatric Treatment · doi:10.1192/apt.bp.112.011023 · Cited by 12
The Role of Free and Cued Selective Reminding Test in Predicting [ 18 F]Florbetaben PET Results in Mild Cognitive Impairment and Mild Dementia
Spallazzi, M., Michelini, G., Barocco, F., Dieci, F., Copelli, S., Messa, G., Scarlattei, M., Pavesi, G., Ruffini, L., & Caffarra, P. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-190950 · Cited by 11
Introduction to Cognitive Screening Instruments: Rationale, Desiderata, and Assessment of Utility
Larner, A. J. (2012) · Springer eBooks · doi:10.1007/978-1-4471-2452-8_1 · Cited by 13
Straightforward synthesis of PET tracer precursors used for the early diagnosis of Alzheimers disease through Suzuki–Miyaura cross-coupling reactions
Bort, G., Veitía, M. S., & Ferroud, C. (2013) · Tetrahedron · doi:10.1016/j.tet.2013.06.085 · Cited by 11
Amyloid imaging in Alzheimer's disease: A literature review
Saidlitz, P., Voisin, T., Vellas, B. J., Payoux, P., Gabelle, A., Formaglio, M., & Delrieu, J. (2014) · The journal of nutrition health & aging · doi:10.1007/s12603-014-0507-3 · Cited by 12
Research Participant Interest in Learning Results of Biomarker Tests for Alzheimer Disease
Goswami, S., Hartz, S. M., Oliver, A., Jackson, S., Ogungbenle, T., Evans, A., Linnenbringer, E. L., Moulder, K. L., Morris, J. C., & Mozersky, J. T. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.2919 · Cited by 10
Self-citation
Nuclear Medicine Diagnostic Techniques in the Era of Pathophysiology-Based CSF Biomarkers for Alzheimer's Disease
Weih, M., Degirmenci, Ü., Kreil, S., Suttner, G., Schmidt, D., Kornhuber, J., Lewczuk, P., & Kuwert, T. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-0020 · Cited by 10
Design and validation of the 1-week memory battery for assessing episodic memory and accelerated long-term forgetting in cognitively unimpaired subjects.
Rami, L., León, M., Valech, N., Coll‐Padrós, N., Bosch, B., Olives, J., Salinero, A., Pérez‐Millan, A., Molinuevo, J. L., Sánchez‐Valle, R., et al. (2023) · Neuropsychology · doi:10.1037/neu0000879 · Cited by 9
A nonlinear meccano for Alzheimer's emergence by amyloid β-mediated glutamatergic hyperactivity
Bonifazi, G., Luchena, C., Gaminde‐Blasco, A., Ortiz-Sanz, C., Capetillo‐Zarate, E., Matute, C., Alberdi, E. M., & Pittà, M. D. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106473 · Cited by 9
Position paper of the Italian Society for the study of Dementias (Sindem) on the proposal of a new Lexicon on Alzheimer disease
Musicco, M., Padovani, A., Sorbi, S., Scarpini, E. A., Caffarra, P., Cappa, S. F., Clerici, F., Tabaton, M., Caltagirone, C., Bonavita, V., et al. (2011) · Neurological Sciences · doi:10.1007/s10072-011-0825-8 · Cited by 9
Protocol of the Cognitive Health in Ageing Register: Investigational, Observational and Trial Studies in Dementia Research (CHARIOT): Prospective Readiness cOhort (PRO) SubStudy
Udeh‐Momoh, C. T., Watermeyer, T., Price, G. J., Loots, C. A. D. J., Reglińska-Matveyev, N., Ropacki, M. T., Ketter, N., Fogle, M., Raghavan, N., Arrighi, M., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-043114 · Cited by 9
Polymorphism in the MAGI2 Gene Modifies the Effect of Amyloid β on Neurodegeneration
Kim, H., Lee, T., Choi, J. K., & Jeong, Y. (2020) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000422 · Cited by 9
Rare and unusual dementias
Gupta, S., Fiertag, O., & Warner, J. P. (2009) · Advances in Psychiatric Treatment · doi:10.1192/apt.bp.107.003558 · Cited by 11
Estimating the Temporal Evolution of Alzheimer's Disease Pathology with Autopsy Data
Royall, D. R., & Palmer, R. F. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120430 · Cited by 7
Beyond diagnosis: What biomarkers are teaching us about the “bio”logy of Alzheimer disease
Rabinovici, G. D., & Roberson, E. D. (2010) · Annals of Neurology · doi:10.1002/ana.22020 · Cited by 7
Using stable isotope labeling to advance our understanding of Alzheimer’s disease etiology and pathology
Hark, T. J., & Savas, J. N. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15298 · Cited by 7
Implementation of [18F]-labeled amyloid brain PET imaging biomarker in the diagnosis of Alzheimer’s disease
Thientunyakit, T., Sethanandha, C., Muangpaisan, W., Chawalparit, O., Arunrungvichian, K., Siriprapa, T., Thongpraparn, T., Chanachai, R., & Gelovani, J. G. (2018) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000000787 · Cited by 7
Uncovering atrophy progression pattern and mechanisms in individuals at risk of Alzheimer's disease
Tremblay, C., Rahayel, S., Pastor‐Bernier, A., St‐Onge, F., Vo, A., Rheault, F., Daneault, V., Morys, F., Rajah, N., Villeneuve, S., et al. (2025) · Brain Communications · doi:10.1093/braincomms/fcaf099 · Cited by 8
Self-citation
Dental X-ray exposure and Alzheimer’s disease: A hypothetical etiological association
Rodgers, C. C. (2011) · Medical Hypotheses · doi:10.1016/j.mehy.2011.03.016 · Cited by 6
Integrating the molecular and the population approaches to dementia research to help guide the future development of appropriate therapeutics
Hunter, S., & Brayne, C. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.12.015 · Cited by 6
Methods for Assessing the Person with Alzheimer's Disease: Integrating Person-Centered and Diagnostic Approaches to Assessment
Mast, B. T. (2012) · Clinical Gerontologist · doi:10.1080/07317115.2012.702647 · Cited by 6
Molecular PET imaging in multicenter Alzheimer’s therapeutic trials: current trends and implementation strategies
Seibyl, J. P., Zubal, I. G., Jennings, D. L., MAREK, K. L., & Doraiswamy, P. M. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.168 · Cited by 6
The Role of Neuropsychology in Prodromal Dementia
Benke, T. (2011) · Neurodegenerative Disease Management · doi:10.2217/nmt.11.34 · Cited by 6
Vers une nouvelle définition de la maladie d’Alzheimer
Dubois, B. (2013) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)31632-2 · Cited by 6
Clinical Assessment of Amyloid Imaging in Alzheimer's Disease: A Systematic Review of the Literature
Wahlster, P., Niederländer, C., Kriza, C., Schaller, S., & Kolominsky‐Rabas, P. L. (2013) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000351679 · Cited by 8
Neue diagnostische Methoden bei Demenzen
Wiltfang, J. (2015) · Der Nervenarzt · doi:10.1007/s00115-014-4177-5 · Cited by 5
Mosaic LSM: A Liquid State Machine Approach for Multimodal Longitudinal Data Analysis
Budhraja, S., Singh, B., Doborjeh, M., Doborjeh, Z., Tan, S. C. W., Lai, E. M.-K., Goh, W. W. B., & Kasabov, N. K. (2023) · International Joint Conference on Neural Networks (IJCNN) · doi:10.1109/ijcnn54540.2023.10191256 · Cited by 5
Modeling clustered activity increase in amyloid-beta positron emission tomographic images with statistical descriptors
Shokouhi, S., Rogers, B. P., Kang, H., Ding, Z., Claassen, D. O., Mckay, J., & Riddle, W. R. (2015) · Clinical Interventions in Aging · doi:10.2147/cia.s82128 · Cited by 6
The Amyloid Precursor Protein: More than Just Amyloid- Beta
Jevtic, S. D., & Provias, J. (2019) · Journal of Neurology and Experimental Neuroscience · doi:10.17756/jnen.2019-045 · Cited by 5
Biomarkers of Alzheimer′s Disease: From Central Nervous System to Periphery?
Mossello, E., Ballini, E., Mello, A. M., Tarantini, F., Simoni, D., Baldasseroni, S., & Marchionni, N. (2010) · International Journal of Alzheimer s Disease · doi:10.4061/2011/342980 · Cited by 5
Cognitive Performance and Cerebrospinal Fluid Markers in Preclinical Alzheimer’s Disease: Results from the Gothenburg H70 Birth Cohort Studies
Rådestig, M. A., Skoog, J., Zetterberg, H., Kern, J., Zettergren, A., Sacuiu, S. F., Wærn, M., Wetterberg, H., Blennow, K., Skoog, I. G., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200751 · Cited by 5
Aβ Imaging in Aging, Alzheimer’s Disease and Other Neurodegenerative Conditions
Villemagne, V. L., Fodero‐Tavoletti, M. T., Yates, P. A., Masters, C. L., & Rowe, C. C. (2014) · Springer eBooks · doi:10.1007/978-3-642-54307-4_10 · Cited by 4
Predicting Cognitive Decline and Dementia with the Newly Normed SKT Short Cognitive Performance Test
Stemmler, M., Hessler, J. B., & Bickel, H. (2019) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000497308 · Cited by 4
Biomarkers and the diagnosis of preclinical dementia
Lilford, P., & Hughes, J. C. (2018) · BJPsych Advances · doi:10.1192/bja.2018.28 · Cited by 4
ACR–ACNM–ASNR–SNMMI Practice Parameter for the Performance of Brain PET/CT Imaging in Dementia
Tu, R. K., Esposito, G., Agarwal, A., Akin, E. A., Catana, C., Chiang, G. C.-Y., Colletti, P. M., Dhingra, J., Kuo, P. H., Franceschi, A. M., et al. (2026) · American Journal of Neuroradiology · doi:10.3174/ajnr.a9105 · Cited by 3
Les marqueurs de la maladie d’Alzheimer prodromale
de Souza, L. C., Sarazin, M., Uspenskaya, O., Habert, M., Lamari, F., Lehéricy, S., & Dubois, B. (2012) · Revue Neurologique · doi:10.1016/j.neurol.2012.07.005 · Cited by 6
Dementias
Apostolova, L. G., DeKosky, S. T., & Cummings, J. L. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0434-1.00091-8 · Cited by 3
Klinisch-validierte molekulare Biomarker neurodegenerativer Demenzerkrankungen
Wiltfang, J. (2014) · Der Nervenarzt · doi:10.1007/s00115-014-4086-7 · Cited by 3
Alzheimer disease
Roe, C. M., & Rentz, D. M. (2013) · Neurology · doi:10.1212/wnl.0b013e31828cade3 · Cited by 3
Self-citation
Cerebral lactate metabolism and memory: Implications for Alzheimer's disease
Harris, R. A. (2017) · Scholarship@Western (Western University) · Cited by 3
The Ethics of Biomarker-Based Preclinical Diagnosis of Alzheimer’s Disease
Kurz, A., & Lautenschlager, N. T. (2018) · Neuromethods · doi:10.1007/978-1-4939-7674-4_17 · Cited by 3
Different Treatment Stages in Medical Diagnosis using Fuzzy Membership Matrix
Sundaresan, T., Sheeja, G., & Govindarajan, A. (2018) · Journal of Physics Conference Series · doi:10.1088/1742-6596/1000/1/012094 · Cited by 3
Coupled support tensor machine classification for multimodal neuroimaging data
Li, P., Sofuoglu, S. E., Aviyente, S., & Maiti, T. (2022) · Statistical Analysis and Data Mining The ASA Data Science Journal · doi:10.1002/sam.11587 · Cited by 4
Uncovering pathology, subjective cognitive complaints, and sex in early Alzheimer's disease
Boutin, S., Houzé, B., Binette, A. P., Brambati, S. M., & Initiative, A. D. N. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251393268 · Cited by 2
Plasma biomarkers in neuropsychiatric syndromes: A narrative review
Ismail, Z., Guan, D. X., Babulal, G. M., Bateman, J. R., Cantillon, M., Creese, B., D’Antonio, F., Fischer, C. E., Gatchel, J. R., Ghahremani, M., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251392185 · Cited by 3
A Call for New Thoughts About What Might Influence Human Brain Aging
DeCarli, C. S. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.33 · Cited by 2
Imaging Biomarkers for Diagnosis, Prognosis and Treatment of Alzheimer's Disease
Skovronsky, D., & Feuerstein, G. (2012) · Frontiers in neuroscience · doi:10.1201/b11986-4 · Cited by 2
A Truncated 14-Amino-Acid Myelin Protein-Zero-Targeting Peptide for Fluorescence-Guided Nerve-Preserving Surgery
Berehova, N., van Meerbeek, M. P., Azargoshasb, S., van Willigen, D. M., Slof, L. J., Lavasani, S. N., van Oosterom, M. N., van Leeuwen, F. W. B., & Buckle, T. (2023) · Biomolecules · doi:10.3390/biom13060942 · Cited by 2
Predicting cognitive decline in older people by structural and molecular imaging
Teipel, S. J., Tang, Y., & Boccardi, M. (2023) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001172 · Cited by 2
Irreversible modifications of chromatin and the nuclear lamina: A review inside the nuclear origin of Alzheimer’s disease
Gil, L., Capdeville, G., Rodríguez‐Leyva, I., Niño, S. A., & Jiménez-Capdeville, M. E. (2021) · Revista de Fomento Social · doi:10.24875/rmn.20000108 · Cited by 2
Diagnosis of Dementia Using Nuclear Medicine Imaging Modalities
Merissa, N., Garrett, M., & Scott, P. J. H. (2011) · InTech eBooks · doi:10.5772/25283 · Cited by 2
Biomarkers in Alzheimer’s Disease—Perspectives for the Future
Cummings, J. L. (2010) · touchREVIEWS in Neurology · doi:10.17925/usn.2010.06.01.23 · Cited by 2
The Challenge and Public Health Implications of Alzheimer Overdiagnosis in the Oldest Old
Fotuhi, M. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.138 · Cited by 2
Beyond the Dawning of the Age of Biomarkers
Blacker, D. (2010) · American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3181f52877 · Cited by 2
Amyloid imaging for Alzheimer's disease
Kerchner, G. A. (2011) · Expert Opinion on Medical Diagnostics · doi:10.1517/17530059.2011.617365 · Cited by 2
Advancements in Positron Emission Tomography/Magnetic Resonance Imaging and Applications to Diagnostic Challenges in Neuroradiology
Kure, A. J., Savas, H., Hijaz, T. A., Hussaini, S. F., & Korutz, A. (2021) · Seminars in Ultrasound CT and MRI · doi:10.1053/j.sult.2021.07.002 · Cited by 2
Review of Treatment for Late-Life Depression
Hay, K., Stageman, W., & Allan, C. L. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108594714.021 · Cited by 2
Psychosocial Interventions in Dementia
Kiridoshi, A. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108594714.019 · Cited by 2
Effect of aldehyde dehydrogenase and alcohol dehydrogenase inhibitors and ethanol on blood and liver ketone bodies in the rat.
Pronko, P. S., Zimatkin, S. M., & Kuz'mich, A. B. (1994) · PubMed · Cited by 2
Faculty Opinions recommendation of Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease.
Perani, D. (2011) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.8343973.8791070 · Cited by 2
Molecular Imaging in Alzheimer’s Disease
Herholz, K. (2010) · touchREVIEWS in Neurology · doi:10.17925/usn.2010.06.02.28 · Cited by 2
Back to the Plaque
Nelson, R. B. (2010) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(10)45019-8 · Cited by 2
Alcohol Misuse in Older People
Rao, R., & CROME, I. B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108594714.009 · Cited by 1
Aβ Imaging in Aging, Alzheimer’s Disease, and Other Neurodegenerative Conditions
Villemagne, V. L., Doré, V., Burnham, S. C., & Rowe, C. C. (2020) · Springer eBooks · doi:10.1007/978-3-030-53168-3_10 · Cited by 2
Pharmacological Characterization of Ruellia tuberosa Ethanolic Extract in a Rodent Model of Cognitive Impairment
Kumar, R., & Tyagi, N. (2025) · Recent Advances in Inflammation & Allergy Drug Discovery · doi:10.2174/0127722708364435250604032539 · Cited by 1
Dementia Due to Neurodegenerative Disease: Molecular Imaging Findings
Ossenkoppele, R., Booij, J., Scheltens, P., & van Berckel, B. N. M. (2014) · Springer eBooks · doi:10.1007/978-3-642-54307-4_9 · Cited by 1
Exploration clinique des troubles cognitifs chez les sujets âgés
Hugonot-Diener, L., Duron, E., Labouree, F., & Rigaud, A. (2012) · Encyclopédie médico-chirurgicale. Psychiatrie · doi:10.1016/s0246-1072(12)70019-6 · Cited by 1
Translational Research in Alzheimer’s Disease for Development of Antibody-Based Therapeutics
Yuen, E., Liu, E., & Kinney, G. G. (2012) · Springer eBooks · doi:10.1007/978-1-4419-5955-3_14 · Cited by 1
Biomarkers for Alzheimer's Dementia : Focus on Neuroimaging
Won, W. Y., & Lee, C. U. (2011) · Saengmul jeongsin euihag/Saengmul jeongsin uihak · Cited by 1
Molecular Imaging and Precision Medicine in Dementia and Movement Disorders
Mallik, A. K., Drzezga, A. E., & Minoshima, S. (2016) · PET Clinics · doi:10.1016/j.cpet.2016.08.003 · Cited by 1
Applications of fMRI to Neurodegenerative Disease
Mahmoud, S. Y., Moon, D., Lee, J. K., & Jones, S. E. (2023) · Springer eBooks · doi:10.1007/978-3-031-10909-6_36 · Cited by 1
Neuropsychological and clinical variables associated with cognitive trajectories in patients with Alzheimer's disease
Riello, M., Moroni, M., Bovo, S., Ragni, F., Buganza, M., Giacopo, R. D., Chierici, M., Gios, L., Pardini, M., Massa, F., et al. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1565006 · Cited by 1
MRI- and PET-Based Imaging Markers for the Diagnosis of Alzheimer’s Disease
Teipel, S. J., Sperling, R. A., Skudlarski, P., Jack, C. R., Hampel, H. J., Fellgiebel, A., & Herholz, K. (2012) · Advances in biological psychiatry · doi:10.1159/000335393 · Cited by 1
Amyloid PET: Its diagnostic potential compared to FDG
Herholz, K. (2011) · Médecine Nucléaire · doi:10.1016/j.mednuc.2011.02.007 · Cited by 1
Utilidad de la neuroimagen amiloidea en Neurología asistencial
Méndez, P. C., Cohen, G., Russo, M. J., Suarez, M. F., Nahas, F., Russo, G., Claudio, W., Paz, S., Leonardo, T., Campos, J., et al. (2014) · Neurología Argentina · doi:10.1016/j.neuarg.2014.02.003 · Cited by 1
Future Perspectives of Alzheimer Disease Research
Iwatsubo, T. (2011) · TRENDS IN THE SCIENCES · doi:10.5363/tits.16.7_57 · Cited by 1
Molecular Imaging in Late-Life Depression
Kumar, A., Ajilore, O., Forester, B. P., Deseda, J., Woodward, M. R., & Rhodes, E. (2013) · Oxford University Press eBooks · doi:10.1093/med/9780199796816.003.0033 · Cited by 1
Impact of the New Conceptual Framework of Alzheimer’s Disease in Imaging Studies
Dubois, B., Villain, N., Jacova, C., & Uspenskaya, O. (2020) · Springer eBooks · doi:10.1007/978-3-030-53168-3_13 · Cited by 1
Clinical Topics in Old Age Psychiatry
Lilford, P., Adshead, G., & Hughes, J. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108594714 · Cited by 1
What Can Person-Centred Care in Dementia Learn from the Recovery Movement?
Hill, L., Roberts, G. A., & Perkins, R. E. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108594714.018 · Cited by 1
Amyloid Imaging
Shaikh, S. (2022) · Springer eBooks · doi:10.1007/978-981-16-9535-3_13 · Cited by 1
Amyloid imaging in depression: a predictor of Alzheimer’s disease?
Camacho, V., & Lleó, A. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2741-7 · Cited by 1

Authors: Morris, J. C., Roe, C. M., Grant, E. A., Head, D., Storandt, M., Goate, A. M., Fagan, A. M., Holtzman, D. M., & Mintun, M. A.
Affiliations: Washington University in St. Louis (US)
ORCID: Morris, John C.
Roe, Catherine M.
Head, Denise
Goate, Alison M.
Fagan, Anne M.
Holtzman, David M.
Venue: Archives of Neurology
Publisher: American Medical Association (AMA)
Published: 2009-12-01
Volume: 66
Issue: 12
Pages: 1469-75
ISSN: 0003-9942 (ISSN-L)
DOI: 10.1001/archneurol.2009.269
PMC: PMC2798814
OpenAlex: W2031489026
Cited by: 476
References: 57
Citations by year: 2026: 5 · 2025: 7 · 2024: 4 · 2023: 14 · 2022: 10 · 2021: 15 · 2020: 46 · 2019: 13 · 2018: 17 · 2017: 24 · 2016: 22 · 2015: 24 · 2014: 43 · 2013: 58 · 2012: 50
FWCI: 35.46
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Archives of Neurology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (UL1TR000448)
National Institute on Aging (P 50 AG05681, P50AG005681, P01 AG0 3991, P01AG003991, P01AG026276)
National Center for Research Resources (UL1RR024992)
National Center for Advancing Translational Sciences
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
Keywords: preclinical Alzheimer's disease, Pittsburgh compound B, amyloid PET, conversion to dementia, very mild dementia, cognitively normal older adults, Clinical Dementia Rating, episodic memory decline, visuospatial performance, entorhinal cortex, risk prediction
MeSH terms: Aged, Aged, 80 and over, Alzheimer Disease, Aniline Compounds, Carbon Radioisotopes, Cognition, Cognition Disorders, Female, Follow-Up Studies, Humans, Longitudinal Studies, Male, Middle Aged, Predictive Value of Tests, Thiazoles, Cohort Studies, Disease Progression, Positron-Emission Tomography

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Pittsburgh Compound B Imaging and Prediction of Progression From Cognitive Normality to Symptomatic Alzheimer Disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks